JMJiacheng Mo

Jiacheng Mo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiacheng Mo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Jianhao Huang

    Department of Endocrinology and Metabolism of Guangxi Academy of Medical Sciences, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People’s Republic of China

    3 shared publications
  • Qiu Wang

    Department of Endocrinology and Metabolism of Guangxi Academy of Medical Sciences, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People’s Republic of China

    3 shared publications
  • Wensheng Lu

    Department of Endocrinology and Metabolism, National Key Clinical Construction Specialty, Guangxi Academy of Medical Sciences & The People’s Hospital of Guangxi Zhuang Autonomous Region, China

    3 shared publications
  • Xiuxian Huang

    Department of Endocrinology and Metabolism of Guangxi Academy of Medical Sciences, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People’s Republic of China

    3 shared publications
  • Zhenwei Zhai

    Department of Endocrinology and Metabolism of Guangxi Academy of Medical Sciences, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People’s Republic of China

    3 shared publications
  • Jingxia Sun

    Department of Endocrinology and Metabolism, Guangxi Academy of Medical Sciences and the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Correlation Between the Controlled Attenuation Parameter and the Prevalence of T2DM in Southern China: A Retrospective Cross-Sectional Study

    by Xingye Wu, Ruibing Qi, Jiaqin Jiang, Quan Lu, Xiaoying Chen, Jiacheng Mo, Jinming Yu, Zhengming Li

    Objective: To explore the relationship between controlled attenuation parameters (CAP) of the liver and the risk of type 2 diabetes mellitus (T2DM), and to determine the optimal cutoff value of CAP for predicting T2DM. Methods: This study employed a cross-sectional study design, enrolling 7035 participants. CAP values were measured using hepatic transient elastography, and participants were categorized into low (≤ 231 dB/m), middle (232~269 dB/m), and high (≥ 270 dB/m) groups. Multivariate logistic regression analysis was used to assess the association between CAP and T2DM, and the optimal cutoff value was determined using receiver operating characteristic (ROC) curves. Results: After adjusting for potential confounders, participants in the high-CAP group had a significantly greater risk of developing T2DM than did those in the low-CAP group (OR=1.545; 95% CI=1.263– 1.890; p< 0.001). Stratified analyses revealed that compared with a low CAP, a 1.0-increased CAP was associated with a 0.852-fold increased T2DM risk in people aged < 55 years (OR=1.852; 95% CI=1.405– 2.441; p< 0.001) and a 0.6-fold increased T2DM risk in overweight patients (BMI≥ 24 kg/m2) (OR=1.600; 95% CI=1.127– 2.271; p=0.009). ROC analysis revealed an optimal CAP cutoff value of 246.5 dB/m for T2DM prediction, with an area under the curve of 0.569 (specificity=48.2%, sensitivity=64.2%). Conclusion: CAP levels are associated with a dose-response relationship with the risk of T2DM, particularly in younger and overweight populations. Although CAP has limited predictive value on its own, it can be used as an auxiliary indicator for T2DM risk screening.


  • Open Access

    Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study

    by Xiuxian Huang, Zhengming Li, Zhenwei Zhai, Qiu Wang, Rongyan Wei, Jiacheng Mo, Jianhao Huang, Wensheng Lu

    Aim: Metabolic dysfunction-related fatty liver disease (MAFLD) is closely related to metabolic disorders. However, the relationship between MAFLD and the prognosis in diabetic foot ulcers (DFUs) remains unclear. This study aimed to explore the association between MAFLD and the risk of major adverse cardiac and cerebral events (MACCEs) in patients with DFUs. Methods: 889 inpatients with DFUs (PEDIS/TEXAS mild and above) were included in this study from 2013 to 2023. All participants were placed into non-MAFLD (n = 643) and MAFLD (n = 246) groups and followed up every 6 months for 10.9 years with a median of 63 months through in-person outpatient interviews and family fixed-line telephone visits. The association between MAFLD and the risk of MACCEs was evaluated through Multivariate Cox regression analyses, Stratified analyses and Kaplan-Meier survival analyses. Results: Of the 889 subjects, 214 (24.07%) experienced MACCEs. Multivariate Cox regression analysis showed that MAFLD was independently associated with MACCEs (P < 0.001), of which with non-fatal myocardial infarction (P = 0.04), non-fatal stroke (P = 0.047), coronary artery revascularization (P = 0.002), heart failure (P = 0.029), and all-cause mortality (P = 0.021), respectively. The stratified analysis revealed that compared with non-MAFLD (HR=1), DFUs with MAFLD had a 2.64-fold increased risk for MACCEs (P < 0.001; P for interaction = 0.001) in peripheral arterial disease (PAD) subgroup. Kaplan-Meier analysis evidenced that the MAFLD group had a higher cumulative incidence of MACCEs (log-rank, all P < 0.05). Conclusion: MAFLD is a high-risk factor for MACCEs in patients with DFUs. The findings will remind clinicians to pay more attention to MAFLD in patients with DFUs, especially in patients with DFUs combined with PAD as early as possible in clinical practice and adopt timely effective intervention strategies to prevent the occurrence of MACCEs to improve the clinical prognosis in patients with DFUs.


  • Open Access

    Triglyceride Glucose Index is Strongly Associated with a Fragility Fracture in Postmenopausal Elderly Females with Type 2 Diabetes Mellitus Combined with Osteoporosis: A 6-Year Follow-Up Study

    by Jiangmei Pan, Xiuxian Huang, Qiu Wang, Jingxia Sun, Zhenwei Zhai, Jiacheng Mo, Jianhao Huang, Wensheng Lu

    Purpose: The triglyceride glucose (TyG) index serves as an indicator of insulin resistance (IR), which is also associated with bone metabolism. However, research on the relationship between the TyG index and a fragility fracture in individuals with type 2 diabetes mellitus (T2DM) or osteoporosis (OP) remains sparse. This study aims to explore the association between the TyG index and fragility fracture risk in postmenopausal elderly females with T2DM combined with OP based on an ambispective cohort study. Patients and Methods: A total of 220 postmenopausal women hospitalized with T2DM combined with OP between January 2015 and December 2020 were eligible for inclusion in this study. All participants were followed up every 6 months for 6 years with a median of 42 months. According to the tertiles of the TyG index, participants were divided into three groups: low-level (≤ 8.79, n =73), moderate-level (8.80– 9.32, n=73), and high-level (≥ 9.33, n=74). The association between the TyG index and fragility fracture risk was then assessed. Results: Out of 220 patients, 46 experienced fragility fracture events (20.9%). Multivariate Cox regression analysis showed that the TyG index was positively associated with a fragility fracture in postmenopausal women with T2DM combined with OP. Furthermore, compared to the low-level group, with the TyG index level increase by 1.0, the risk for fragility fracture increased 1.293-fold in the high-level group (HR=2.293, 95% CI=1.007– 5.221, P < 0.05). Kaplan-Meier survival analysis indicated that fragility fractures were more likely to occur in patients with high levels of TyG index (log-rank, all P < 0.05). Conclusion: Our study showed that the TyG index was strongly associated with a fragility fracture in postmenopausal women with T2DM combined with OP. Therefore, special attention should be paid to postmenopausal elderly females with T2DM combined with OP in routine clinical practice.


  • Open Access

    The Ratio of Serum Uric Acid to Glycosylated Haemoglobin as a Predictor of All-Mortality in Elderly Patients with Diabetic Foot Ulcers: A Longitudinal Cohort Study

    by Xiuxian Huang, Licai Deng, Jianhao Huang, Jingxia Sun, Qiu Wang, Jiacheng Mo, Zhenwei Zhai, Yuechou Nong, Wensheng Lu

    Aim: To clarify the relationship between serum uric acid (UA) and glycosylated hemoglobin (UA/HbA1c) ratio and all-cause mortality in patients with diabetic foot ulcers (DFUs). Methods: A total of 172 inpatients with DFUs (PEDIS grades 2– 4) were eligible for inclusion in this study from 2018 to 2023. This was a retrospective, longitudinal cohort study. All subjects were followed up every 6 months for a median of 60 months. According to the cutoff value of the UA/HbA1c ratio of 39.07 obtained from ROC analysis, the participants were divided into two groups: low-level (≤ 39.07, n = 107) and high-level (> 39.07, n = 65) groups. The correlation between UA/HbA1c ratio and all-cause mortality was also evaluated by Cox regression analysis TheKaplan-Meier survival curve analysis and Log rank tests were used to assess the incidence rates of all-cause mortality. The contribution rate of risk factors was estimated by the population-attributable risk percentage (PAR%) analysis. Results: ROC analysis showed that the optimal cutoff values for UA and the UA/HbA1c ratio were 372 μmol/L and 39.07, respectively. Multivariate Cox regression analysis indicated that a high UA/HbA1c ratio (HR =4.63; 95% CI = 2.004– 10.7, P < 0.001) was independently associated with a high risk of all-cause mortality in patients with DFUs. Stratified analysis indicated that subjects aged ≥ 60 years had a greater risk of all-cause mortality associated with a high UA/HbA1c ratio (HR = 4.450; 95% CI = 1.711– 11.574, P = 0.002). Kaplan-Meier survival analysis showed that all-cause mortality had a significant positive association with a high UA/HbA1c ratio (log-rank, P < 0.001) and a significant negative correlation with the lowered HbA1c level (< 6.5%) after a follow-up of 32 months (log-rank, P < 0.001). The population attributable risk percentage (PAR%) analysis suggested that the contribution rate of the high-level UA/HbA1c ratio to all-cause mortality was 33.7%, which was much greater than the 19.69% of UA. Conclusion: In brief, our study showed that for every 1.0% increase in the UA/HbA1c ratio, the all-cause mortality rate in elderly patients with DFUs aged ≥ 60 years increased by 3.45-fold. For elderly patients with DFUs, a safe and effective strategy to reduce all-cause mortality is to strictly control serum UA levels to < 372 μmol/L and appropriately loosen the control goal of HbA1c to ≥ 6.5%.